Related Experiment Video
Updated: Mar 6, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.8K
Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: A cohort study
Xiaodong Wang1, Yan Lai2, Yu Luo1
1Department of Cardiology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Summary
Clopidogrel gene variations affect platelet reactivity and major adverse cardiovascular events in Chinese patients. Specific polymorphisms like CYP2C19*2 and P2Y12 increase risks, while CYP2C19*17 offers protection, without impacting cardiac death rates.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Genetics
Background:
- Clopidogrel is a widely used antiplatelet medication.
- Genetic variations can influence clopidogrel's efficacy and patient outcomes.
- Understanding these genetic effects is crucial for personalized treatment.
Purpose of the Study:
- To investigate the impact of clopidogrel-related gene polymorphisms on platelet reactivity.
- To assess the relationship between these polymorphisms and clinical outcomes in Chinese Han patients undergoing percutaneous coronary intervention.
- To identify specific genetic markers associated with treatment response and adverse events.
Main Methods:
- A cohort of 336 patients receiving percutaneous coronary intervention was studied over 1 year.
- DNA genotyping was performed to assess various alleles, including CYP2C19*2, CYP2C19*3, CYP2C19*17, ABCB1, ITGB3, CYP2C9*3, CYP2B6*9, and P2Y12.
- Platelet reactivity was measured using the VerifyNow assay.
Main Results:
- Clinical endpoints were associated with prior heart disease, stroke, and diabetes.
- High on-treatment platelet reactivity (HTPR) was linked to older age, male gender, hypertension, and chronic renal failure.
- CYP2C19*2 and P2Y12 polymorphisms correlated with increased endpoints and HTPR, while CYP2C19*17 showed reduced platelet reactivity and fewer endpoints.
Conclusions:
- Clopidogrel-related gene polymorphisms significantly influence platelet reactivity and major adverse cardiovascular events in Han Chinese patients.
- The CYP2C19*2 and P2Y12 variants are associated with increased risk, whereas CYP2C19*17 is associated with improved outcomes.
- These genetic factors affect cardiovascular events but do not appear to influence cardiac death.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
76
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:16Drug toxicity: Idiosyncratic Reactions
75
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
75
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
70
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
70
01:27Pharmacogenetics of Drug Metabolism: Overview
74
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
74
01:27Principles of Pharmacogenetics: Types of Genetic Variants
65
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
65